title: Presynaptic dopaminergic neurotransmission mediates amphetamine-induced unconditioned but not amphetamine-conditioned locomotion and defecation in the rat.
abstract: A series of experiments were conducted to investigate the role of presynaptic dopamine (DA) and noradrenaline (NA) neurotransmission in stimulant-unconditioned and conditioned locomotion and defecation. (+)-Amphetamine (AMP, 1.5 mg/kg, s.c.) increased both locomotion and defecation in rats, and both of these effects were conditioned to environmental stimuli. Some groups of rats were treated with DSP4 (50 mg/kg, i.p.), a selective, long-lasting NA neurotoxin, given 7 days prior to conditioning with AMP. This treatment depleted forebrain NA to between 1% and 54% of control levels, depending on the brain region, but did not attenuate either AMP-unconditioned or conditioned locomotion. These results indicate that NA does not mediate either AMP unconditioned or conditioned locomotion. alpha-Methyl-para-tyrosine methyl ester (alpha MPT, 25-50 mg/kg, s.c.), a selective inhibitor of catecholamine synthesis given during conditioning with AMP, attenuated unconditioned AMP-induced locomotion and defecation but did not influence AMP-conditioned locomotion and defecation. Thus, alpha MPT blocked AMP-induced unconditioned locomotion, supporting the hypothesis that the locomotor and defecation stimulant effects of AMP are mediated by DA release. In spite of the attenuation of the direct effects of AMP, alpha MPT did not attenuate AMP-conditioned locomotion or defecation. It is concluded that AMP-induced release of dopamine is responsible for the unconditioned behavioral effects of amphetamine but not for the conditioning of amphetamine-induced locomotion and defecation.
authors.affiliation: Department of Psychiatry, University of Alberta, Edmonton, Canada.
authors.forename: S L
authors.initials: SL
authors.lastname: Di Lullo
authors.forename: M T
authors.initials: MT
authors.lastname: Martin-Iverson
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000661:Amphetamine / Q000494:pharmacology*; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D003216:Conditioning, Operant / Q000187:drug effects*; D003672:Defecation / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008781:Methyltyrosines / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D012701:Serotonin / Q000378:metabolism; D013566:Sympathomimetics / Q000494:pharmacology*; D013569:Synapses / Q000187:drug effects / Q000502:physiology*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology*
chemical_list: D001596:Benzylamines; D008781:Methyltyrosines; D013566:Sympathomimetics; D015102:3,4-Dihydroxyphenylacetic Acid; D012701:Serotonin; C022260:alpha-methyltyrosine methyl ester; D006897:Hydroxyindoleacetic Acid; D000661:Amphetamine; C012102:DSP 4; D004298:Dopamine